<?xml version="1.0"?>
<case>
<name>University of Western Australia v Gray (No 26) (includes corrigendum dated 23 November 2009) [2009] FCA 1229 (30 October 2009)</name>
<AustLII>http://www.austlii.edu.au/au/cases/cth/FCA/2009/1229.html</AustLII>
<citphrases>
<citphrase id="cp1.0" type=cited from="[2008] FCA 1315">intellectual property</citphrase>
<citphrase id="cp1.1" type=cited from="[2008] FCA 1315">assessment of damages</citphrase>
<citphrase id="cp1.2" type=cited from="[2008] FCA 1315">damages under s 79 fair trading act 1987 (wa)</citphrase>
<citphrase id="cp1.3" type=cited from="[2008] FCA 1315">where trial conducted on basis that damages would be separately assessed</citphrase>
<citphrase id="cp1.4" type=cited from="[2008] FCA 1315">where trial judge subsequently appointed to a different court, prior to assessment of damages</citphrase>
<citphrase id="cp1.5" type=cited from="[2008] FCA 1315">whether appropriate to make ruling or declaration stating recoverable heads of damage</citphrase>
<citphrase id="cp1.6" type=cited from="[2008] FCA 1315">no ruling or declaration made</citphrase>
<citphrase id="cp1.7" type=cited from="[2008] FCA 1315">assessment of quantum of damages cannot in these circumstances be detached from identification of heads of damage</citphrase>
<citphrase id="cp1.8" type=cited from="[2008] FCA 1315">causation the ultimate test of damages under s 79 fair trading act 1987</citphrase>
<citphrase id="cp1.9" type=cited from="[2008] FCA 1315">assessment of damages to be conducted by another judge</citphrase>
<citphrase id="cp2.0" type=cited from="[2008] FCA 498">application doc title investigator grant body amount received invention date 28/01/1985 augmentation of effect of chemotherapeutic agents mander, gray, burton rph $10,000 (microspheres) $3,770 (lab assistant) dox* 28/01/1985 (1985-4) augmentation of effect of chemotherapeutic agents mander, gray, burton rph $10,000 (microspheres) $3,770 (lab assistant) 25/07/1985 manipulation of tumour blood flow to facilitate therapy gray uwa special research grant $57,510 for 1986-1987; additional $2060 awarded for 'maintenance' in 1987 sir 25/07/1985 (1986-87) manipulation of tumour blood flow to facilitate therapy gray uwa special research grant $57,510 for 1986-1987; additional $2060 awarded for 'maintenance' in 1987 6/12/1985 treatment of hepatic metastases with intra-hepatic radioactive microspheres mander, burton uwa (faculty of medicine) $3,990 sir 24/03/1986 the utilization of microspheres as vehicles for the accurate and sustained delivery of anti-cancer drugs. hodgkin; mau; burton; gray csiro/uwa collaborative research fund $36, 571 dox* 30/01/1987 the manufacture of chemotherapeutic microspheres with novantrone, floxuridine and mitomycin-c c jones; burton; gray rph $3,000 dox* 26/06/1987 (1987-4) hyperthermia of tumours utilising hysteresis heat loss from selectively targeted ferromagnetic particles gray, detchon clive and vera ramaciotti foundation research nil. grant is marked "unsuccessful" 27/11/1987 assessment of the ability of 5-fu to prevent liver and peritoneal metastases from colonic carcinoma archer, gray uwa</citphrase>
<citphrase id="cp2.1" type=cited from="[2008] FCA 498">faculty of medicine not in evidence 9/12/1987 polymer mediated chemotherapy of localised tumours gray, burton rph $6,240 dox* 16/08/1988 manufacture of sustained release microspheres for 5fu, fudr and mitrozantone burton; trotter cfwa (administered by uwa) $32,330 dox* 28/11/1988 selective internal radiation therapy for metastatic liver cancer gray uwa</citphrase>
<citphrase id="cp2.2" type=cited from="[2008] FCA 498">faculty of medicine $8,800 sir x/x/1988 ** clinical trials in bowel cancer / redistribution of liver blood flow nhmrc $17,000/ $42,000 29/11/1988 electromagnetic radiation induced hyperthermia treatment of liver tumours kelleher uwa</citphrase>
<citphrase id="cp2.3" type=cited from="[2008] FCA 498">faculty of medicine $3,567 thermo* x/x/1988 ** electromagnetic radiation induced hyperthermia treatment of liver tumours medwa $38,750 sought</citphrase>
<citphrase id="cp2.4" type=cited from="[2008] FCA 498">amount received not specified. 26/01/1989 selective internal radiation therapy for the treatment of metastatic liver cancer gray rph $6,518 sir 31/01/1989 electromagnetic radiation induced hyperthermia treatment of liver tumours kelleher; burton rph $3,567 thermo* 31/01/1989 a pilot study of adjuvant sir-therapy burton rph $2,104 sir 24/02/1989 augmentation of the dynamics of adriamycin chemotherapy burton, chen nhmrc (administered by uwa) $117,279.84 for 1990 to 1992 dox 26/06/1989 efficacy of floxuridine transported on ion exchange microspheres burton; chen cfwa (administered by uwa) $36,132 dox 27/08/1989 research grant application entitled 'effect of treatment on immune cell population' gray; codde racs (administered by uwa) not in evidence 16/02/1990 development of ferromagnetic microspheres for treatment of cancer by induced hyperthermia resulting from hysteresis heating s jones rph $5,700 thermo 16/02/1990 formulation of macromolecular conjugates of fudr chen, blackbourn rph $5,700 dox* 16/02/1990 grants 1990-7: optimization programme for sir-therapy gray; burton rph $5,555 28/02/1990 randomised trial of selective internal radiation therapy in liver cancer gray; van hazel nhmrc (administered by uwa) $213,212.68 over 3 years to 31 july 1994 sir 20/06/1990 hyperthermia of tumours utilising hysteresis heat loss from selectively targeted ferromagnetic particles s jones; gray clive and vera ramaciotti foundation research not in evidence thermo 20/06/1990 (1990-8) hyperthermia of tumours utilising hysteresis heat loss from selectively targeted ferromagnetic particles s jones; gray clive and vera ramaciotti foundation research (administered by rph) not in evidence 23/01/1991 therapeutic evaluation of cytotoxic drug carriers codde rph $13,260 dox* 31/01/1991 formulation of sustained release carriers for cisplatin chen, blackbourn rph $9,970 dox 31/01/1991 optimization of magnetic parameters for hyperthermia cancer therapy using hysteresis heating s jones, gray rph $8,994 thermo 3/05/1991 development of complexed doxorubicin-metal ion microspheres hodgkin; mau; burton; chen csiro/uwa collaborative research fund $31,917 dox 11/02/1992 scheduling hyperthermia and chemotherapy burton rph not in evidence 14/02/1992 development of biodegradable magneto</citphrase>
<citphrase id="cp2.5" type=cited from="[2008] FCA 498">responsive microspheres' gray, chen, blackbourn rph $3,680 other projects (thermo*) 19/05/1992 magnetoregulated release of doxorubicin from albumin-heparin microspheres jones; chen cfwa (administered by rph) $37,000 other projects (thermo*) 15/09/1992 development of a hyperthermia research program burton, jones, gray, chen, codde telethon unclear. possibly $50,000 or $40,000 thermo* 2/12/1993 magneto-regulated doxorubicin delivery chen rph $4,350 other projects (thermo*) 2/12/1993 grants 1993-1: in vivo investigation of induced hyperthermia by ferromagnetic hysteresis technique s jones rph $10,010 thermo 2/12/1993 grants 1993-2: magnetoregulated doxorubicin delivery chen rph $4,350 11/02/1994 investigation of microsphere mediated hyperthermia in rabbit tumour model s jones rph $9,650 thermo 7/07/1995 development of a device for evaluation of a rotational hysteresis losses s jones arc (administered by uwa) $12,609 thermo 8/11/1997 the development of targeted products for the treatment of cancer</citphrase>
<citphrase id="cp3.0" type=cited from="[1950] HCA 35">specific performance</citphrase>
<citphrase id="cp3.1" type=cited from="[1950] HCA 35">station property</citphrase>
<citphrase id="cp3.2" type=cited from="[1950] HCA 35">purchase</citphrase>
<citphrase id="cp3.3" type=cited from="[1950] HCA 35">option</citphrase>
<citphrase id="cp3.4" type=cited from="[1950] HCA 35">extension</citphrase>
<citphrase id="cp3.5" type=cited from="[1950] HCA 35">alleged failure to exercise</citphrase>
<citphrase id="cp3.6" type=cited from="[1950] HCA 35">contract</citphrase>
<citphrase id="cp3.7" type=cited from="[1950] HCA 35">provisions</citphrase>
<citphrase id="cp3.8" type=cited from="[1950] HCA 35">conduct of parties</citphrase>
<citphrase id="cp3.9" type=cited from="[1950] HCA 35">alleged mis-representation by purchaser's agent</citphrase>
<citphrase id="cp3.10" type=cited from="[1950] HCA 35">finding of trial judge</citphrase>
<citphrase id="cp3.11" type=cited from="[1950] HCA 35">belated defence</citphrase>
<citphrase id="cp3.12" type=cited from="[1950] HCA 35">practice of appellate court</citphrase>
<citphrase id="cp3.13" type=cited from="[1950] HCA 35">time, essence of contract</citphrase>
<citphrase id="cp3.14" type=cited from="[1950] HCA 35">treasurer's consent to sale</citphrase>
<citphrase id="cp3.15" type=cited from="[1950] HCA 35">failure to obtain within period expressly provided</citphrase>
<citphrase id="cp3.16" type=cited from="[1950] HCA 35">effect</citphrase>
<citphrase id="cp3.17" type=cited from="[1950] HCA 35">"deemed to be cancelled"</citphrase>
<citphrase id="cp3.18" type=cited from="[1950] HCA 35">contract void, or voidable by one or both parties</citphrase>
<citphrase id="cp3.19" type=cited from="[1950] HCA 35">contractual requirement</citphrase>
<citphrase id="cp3.20" type=cited from="[1950] HCA 35">continuation in employment on specified terms and conditions</citphrase>
<citphrase id="cp3.21" type=cited from="[1950] HCA 35">deed between purchaser and employees of vendor</citphrase>
<citphrase id="cp3.22" type=cited from="[1950] HCA 35">national security (economic organization) regulations, regs. 6 (1), (10), 10 (1).</citphrase>
</citphrases>
<citances>
</citances>
<legistitles>
<title id="l0">EVIDENCE ACT 1995 </title>
<title id="l1">EVIDENCE ACT 1995 - SECT 135 General discretion to exclude evidence</title>
<title id="l2">FEDERAL COURT RULES </title>
<title id="l3">FAIR TRADING ACT 1987 </title>
<title id="l4">FAIR TRADING ACT 1987 - SECT 10 </title>
</legistitles>
</case>